ABSTRACT

Introduction: The use of cell-based therapies in the management of sports injuries of the upper limb is increasingly popular despite the limited scientific evidence available for their use. We aim to evaluate the evidence for the use of cell-based therapies in these injuries and recommend areas for further research.

Areas covered: In accordance with a published protocol (PROSPERO; Registration No. CRD42020193258), a comprehensive search of the literature was performed using the MEDLINE and EMBASE databases from inception to June 2020. All human studies reporting on the clinical, histological, or radiological outcomes following the use of cell-based therapies in the management of epicondylitis or rotator cuff pathology were included in this study. This resulted in 22 studies being included in this review, all of which underwent risk of bias assessments.

Expert opinion: The evidence for the use of cell-based therapies in upper limb sports injuries is limited and generally of low quality. Given the heterogeneity in the cell types used, their harvesting methods and cell amounts, future research should be targeted at developing standardization of the reporting of these studies and more direct comparative studies looking at the efficacy of the different cell types.

摘要

简介：尽管可用的科学证据有限，但在上肢运动损伤管理中使用基于细胞的疗法越来越受欢迎。我们旨在评估在这些损伤中使用基于细胞的疗法的证据，并推荐进一步研究的领域。

涵盖的领域：根据已发布的方案（PROSPERO；注册号 CRD42020193258），使用 MEDLINE 和 EMBASE 数据库从开始到 2020 年 6 月进行了全面的文献检索。所有人类研究报告了临床、组织学或放射学本研究包括使用基于细胞的疗法治疗上髁炎或肩袖病变的结果。这导致 22 项研究被纳入本次审查，所有这些研究都进行了偏倚风险评估。

专家意见：在上肢运动损伤中使用基于细胞的疗法的证据有限且质量普遍较低。鉴于所使用的细胞类型、它们的收获方法和细胞数量的异质性，未来的研究应针对这些研究报告的标准化和更直接的比较研究，着眼于不同细胞类型的功效。